PRN Archives - Page 8 of 8

Developments

Echelon reiterates Profound Medical as Top Pick

Echelon Wealth Partners reiterated Profound Medical’s Top Pick status (TSX:PRN; OTCQX:PRFMF) and maintained its “buy” rating and $3 price target. The stock closed at 74 cents on Jan. 9. Analyst Doug Loe writes that...

January 10, 2019

Developments

Profound Medical sees five-fold jump in preliminary Q4 revenue versus Q3

Profound Medical (TSX:PRN; OTCQX:PRFMF) expects total revenue of about $1.6-million for the fourth quarter of 2018, up from about $300,000 for the third quarter last year. For all of 2018, the company expects total...

January 4, 2019

Executive Moves

Profound Medical appoints Ian Heynen as SVP sales and marketing

Profound Medical (TSXV:PRN; OTCQX:PRFMF) appointed Ian Heynen as SVP of sales and marketing. Mr. Heynen brings to Profound more than 15 years of progressive leadership experience, working with medical device companies...

April 23, 2018

Developments

Profound Medical Q2 Top Pick at Paradigm Capital

Paradigm Capital has made Profound Medical (TSXV:PRN; OTCQX:PRFMF) its second quarter Top Pick, saying the next three-to-four months are expected to be an accretive time for Profound. Analyst Rahul Sarugaser writes that...

April 12, 2018

Markets

Paradigm ups Profound Medical PT to $3

Paradigm Capital raised its price target for Profound Medical (TSXV:PRN) to $3 from $2.25 after the company completed an upsized equity financing of $34.5-million. The stock closed at $1.05 on March 20. “We see this...

March 21, 2018

Markets

Profound Medical closes upsized bought deal financing

Profound Medical (TSXV:PRN) closed a previously announced bought deal financing for gross proceeds of $34.5-million, including the exercise of the underwriters’ over-allotment option. Net proceeds are expected to be...

March 20, 2018

Feature

Profound makes leap to platform company from prostate product

By Len Zehr Arun Menawat, CEO With its recent acquisition of Royal Philips’ (NYSE:PHG; AEX:PHIA) Sonalleve business, Profound Medical (OTCQX:PRFMF; TSXV:PRN) is making the leap from a medical device company focused on...

September 5, 2017

Feature

Profound Medical’s TULSA-PRO pilot OUS launch: paving the way for global growth

By Len Zehr After nearly a decade of R&D, Profound Medical (OTCQX:PRFMF; TSXV:PRN) is now conducting a pilot launch of its TULSA-PRO medical device to ablate tissue in localized prostate cancer within key European...

March 28, 2017

Feature

Profound Medical readies pivotal clinical trial of TULSA-PRO

By Len Zehr After receiving CE Mark approval last month of its minimally invasive transurethral ultrasound technology for the ablation of benign and malignant prostate tissue, known as TULSA-PRO, Profound Medical (TSX...

May 3, 2016

Tag - PRN

Echelon reiterates Profound Medical as Top Pick

Profound Medical sees five-fold jump in preliminary Q4 revenue versus Q3

Profound Medical appoints Ian Heynen as SVP sales and marketing

Profound Medical Q2 Top Pick at Paradigm Capital

Paradigm ups Profound Medical PT to $3

Profound Medical closes upsized bought deal financing

Profound makes leap to platform company from prostate product

Profound Medical’s TULSA-PRO pilot OUS launch: paving the way for global growth

Profound Medical readies pivotal clinical trial of TULSA-PRO

Subscribe